When a founder finally holds an FDA clearance letter, the temptation is to treat it as the finish line. It is closer to a permission slip. Neurovalens got one of the good ones this month. On July 2, MedCity News reported that the FDA granted De Novo authorization to Modius Spero, the first neuromodulation device cleared to treat the symptoms of post-traumatic stress disorder. That is a genuine milestone. It also opens a gap most hardware founders underestimate, because a clearance tells you that you are allowed to sell, not that anyone is set up to pay you.
What the De Novo actually buys
Modius Spero is a headset worn for thirty minutes a day, usually in the evening, that sends low-level electrical pulses to the vestibular nerve behind each ear. The clearance rests on a US study of 383 adults with diagnosed PTSD, run over twelve weeks, where roughly two-thirds of participants reported clinically meaningful symptom improvement against an active sham group. Those are not soft numbers for a device treating a condition with few good options.
The pathway matters as much as the data. The FDA used De Novo because there was no existing device type to match, which means Neurovalens did not squeeze into someone else’s category. It defined one. When the agency writes the regulation for a first-of-its-kind device, that regulation becomes the standard the next entrant has to meet.
I have been on the writing end of that. At Galen, our De Novo ended with the FDA asking us what the new regulation should say, we sent them a paragraph, and the clearance came back with our words in it. Neurovalens is now the predicate for PTSD neuromodulation. Anyone who follows has to prove they are equivalent to Modius Spero, and Neurovalens’ own next version gets to be equivalent to itself.
A clearance is a door, not a market
The same reporting notes that broad reimbursement is not expected until later in 2027. So the device is cleared today, and the payment machinery that would let a typical clinic bill for it is more than a year out. For most companies that lag is where momentum dies. You have the letter, the press, and the LinkedIn victory lap, then eighteen months of burn while you wait for coverage codes to catch up to your clearance.
This is the part I press hard on with medical-device founders, and it is the deepest vertical I work in. The economics are not a step you run after the product clears. They are the product decision. If the path from cleared to paid is not mapped before the clearance, the clearance funds a waiting room, not a business.
Why veterans get it first
Neurovalens closed that gap with its launch channel. Modius Spero reaches patients through the Department of Veterans Affairs starting this summer, ahead of the 2027 coverage timeline. That is not a consolation channel. The VA is a rare buyer that is both the payer and the provider, it controls its own budget, and it does not have to wait for a national coverage decision to adopt something. It also serves a population where PTSD is common and the need is urgent, so the mission and the math point the same direction.
That is an access play, and access is usually where the value in a hard-tech device actually lives. The da Vinci did not win because any single surgeon got better with it. It won because it grew the number of surgeons who could offer a minimally invasive procedure, so far more patients got one. The same logic holds here. The first job is not universal coverage, it is getting the device to the people who need it through a buyer who can say yes today. If you are commercializing a novel device into a reimbursement lag, find your version of the VA, a single motivated buyer who owns their budget and does not need the broader payer system’s permission.
Dave’s take
A De Novo is one of the best positions in medtech, because you set the standard and you become your own predicate. But the clearance is the start of the work, not the payoff. The teams that turn a first-in-category clearance into a company are the ones who line up a buyer who can pay now while the rest of the market catches up. Neurovalens found that buyer before the coverage codes existed. That sequencing, not the press release, is the part worth studying.
From Dave’s video library
Dave on why a clearance, a demo, or a finished feature is not proof you have a market, and the only proof that counts is a costly yes from a real buyer.
I’m here to help you scale.
Work With DavePrefer a smaller first step? Book a $500 one-hour consultation →
Dave Saunders is the founder of Base Reality Group and a Fractional CPO for hard-tech founders. He was a founder and operator at Galen Robotics, where the surgical-robotics platform earned FDA De Novo authorization in 2023, and he managed a 35-patent portfolio licensed from Johns Hopkins. He wrote Founders Who Finish and publishes The Build. More about Dave →